CGEN

CompugenB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$4.60

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$2.40

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$1.40

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-06

AI commentary

The Q2 print was operationally mixed-to-positive: revenue and EPS were better than the packet's pre-print consensus, while the company maintained its clinical timetable and runway. The Aug. 5 RankAlpha anchor was $2.28, but a clean post-release price-reaction series and verified post-print analyst revisions were unavailable. This remains a cautious, low-coverage biotech monitoring view. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [#PR-2026-08-03]

RankAlpha Sentiment Codex - 2026-08-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-03catalystQ2 2026 beat improved near-term toneMedium impact

Compugen reported Q2 revenue of approximately $2.6 million and a net loss of $0.07 per share, versus the packet's pre-print consensus of $1.61 million and -$0.08 per share. The release also showed a modest year-over-year reduction in net loss. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [SEC Q2 financial statements](https://www.sec.gov/Archives/edgar/data/1119774/000117891326003754/exhibit_99-2.htm) [#PR-2026-08-03] [#SEC-6K-2026-08-03]

2026-11-04eventMAIA-ovarian interim PFS analysisHigh impact

The company said its randomized MAIA-ovarian trial remains on track for median progression-free-survival data by Q1 2027. This is the clearest potential valuation-reset event, but remains binary and clinically uncertain. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [#PR-2026-08-03]

2027-08-06catalystPartnered pipeline progress and extended runwayHigh impact

AstraZeneca is advancing rilvegostomig across 12 Phase 3 trials, while the Gilead-partnered GS-0321 Phase 1 trial is progressing as planned. Compugen reported approximately $125.3 million in cash and investments, no debt, and expected funding into 2029. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [#PR-2026-08-03]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-06 • Updated nightlySource: Internal modelMethodology